Melanoma Antigens

Melanoma antigens represent a diverse group of molecules expressed by melanoma cells that are recognized by the immune system and serve as critical targets in cancer therapy. These antigens can be broadly categorized into melanocyte differentiation antigens (e.g., tyrosinase, MART-1, gp100), cancer-testis antigens (e.g., MAGE, NY-ESO-1, PRAME), and neoantigens, which arise from somatic mutations unique to the tumor. Their biological functions often relate to melanin production, cell growth, and differentiation, but in melanoma, their aberrant expression can contribute to tumor progression and immune evasion. Melanoma antigens are central to the development of immunotherapies and targeted therapies. Immunotherapies aim to stimulate the patient's immune system to recognize and destroy cancer cells, often by blocking immune checkpoints or by using vaccines and adoptive cell therapies that specifically target these antigens. Targeted therapies, on the other hand, focus on specific oncogenic proteins like mutated BRAF or MEK, which are also considered antigens in a broader sense due to their role in driving cancer growth. The identification and characterization of these antigens are also crucial for diagnostic and prognostic biomarkers in melanoma.

Other names

Tumor-associated melanoma antigensMelanoma-associated antigens (MAA)Tumor antigens (melanoma)

Melanoma antigens are a diverse group of molecules that serve as targets for various therapeutic strategies. Drugs targeting these antigens primarily work by stimulating an anti-tumor immune response, either directly or indirectly. This includes blocking immune checkpoint pathways (e.g., PD-1, CTLA-4, LAG-3) to enhance T-cell activity and overcome immune evasion by tumor cells. Some therapies involve the direct lysis of tumor cells by immune cells, such as T-cells, or the adoptive transfer of T-cells specifically engineered to recognize melanoma antigens. Oncolytic viruses like Talimogene laherparepvec replicate within tumor cells, causing their lysis and releasing tumor-derived antigens, which then promote a systemic anti-tumor immune response. Additionally, cancer vaccines are designed to induce antigen-specific T-cell responses against melanoma antigens or neoantigens. For specific oncogenic mutations, targeted therapies inhibit key signaling pathways (e.g., BRAF/MEK pathway) crucial for melanoma cell growth and survival.